MIM
MRNS

MetLife Investment Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

MetLife Investment Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,356
Closed -$238K – 2947
2024
Q1 		$238K Hold
26,356
– – ﹤0.01% 2095
2023
Q4 		$286K Hold
26,356
– – ﹤0.01% 2031
2023
Q3 		$212K Hold
26,356
– – ﹤0.01% 2172
2023
Q2 		$286K Buy
+26,356
New +$226K ﹤0.01% 2046
2022
Q2 		– Sell
-20,363
Closed -$190K – 2922
2022
Q1 		$190K Buy
20,363
+7,928
+64% +$78.8K ﹤0.01% 2381
2021
Q4 		$148K Hold
12,435
– – ﹤0.01% 2246
2021
Q3 		$142K Hold
12,435
– – ﹤0.01% 2278
2021
Q2 		$223K Hold
12,435
– – ﹤0.01% 2095
2021
Q1 		$192K Buy
12,435
+480
+4% +$6.94K ﹤0.01% 2074
2020
Q4 		$146K Sell
11,955
-1
-0% -$14 ﹤0.01% 2137
2020
Q3 		$154K Buy
11,956
+1,052
+10% +$9.08K ﹤0.01% 2014
2020
Q2 		$111K Buy
+10,904
New +$100K ﹤0.01% 2208
2018
Q4 		– Sell
-4,669
Closed -$187K – 2602
2018
Q3 		$187K Buy
+4,669
New +$133K ﹤0.01% 2127

Other funds holding MRNS

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MetLife Investment Management's MRNS Position: Q2 2024 in Review

MetLife Investment Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q2 2024, closing a stake of 26,356 shares — an estimated $238K sold.

MetLife Investment Management first reported a position in MRNS in Q3 2018 and held it in 13 quarters. The position peaked at $286K in Q4 2023. 90 funds tracked by Wall St. Rank hold MRNS as of Q2 2024.

  • MetLife Investment Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q2 2024 after selling out during the quarter.
  • MetLife Investment Management sold 26,356 Marinus Pharmaceuticals, Inc shares in Q2 2024, an estimated $238K.
  • MetLife Investment Management first reported a position in Marinus Pharmaceuticals, Inc in Q3 2018 and held it in 13 quarters.
  • MetLife Investment Management's Marinus Pharmaceuticals, Inc position peaked at $286K in Q4 2023.
  • 90 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q2 2024.

Based on MetLife Investment Management's 13F filing for Q2 2024, filed 13 Aug 2024.